17.93

0.65% 0.1175

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Financials Discussions Forecast

Kura Oncology Inc stock is traded at $17.93, with a volume of 328.59K. It is up +0.65% in the last 24 hours and down -0.64% over the past month. Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Previous Close:

$17.81

Open:

$18

24h Volume:

328.59K

Relative Volume:

0.63

Market Cap:

$1.33B

Revenue:

Net Income/Loss:

$-168.09M

P/E Ratio:

-8.7451

EPS:

-2.05

Net Cash Flow:

$-138.01M

1W Performance:

+3.25%

1M Performance:

-0.64%

6M Performance:

-13.11%

1Y Performance:

+98.95%

1-Day Range:

$17.24

$18.07

1-Week Range:

$16.50

$18.07

52-Week Range:

$8.17

$24.17

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(858) 500-8800

Address

12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA

Employee

142

Twitter

@kuraoncology

Next Earnings Date

2024-11-07

Latest SEC Filings

KURA's Discussions on Twitter

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

11:36 AM

When the Price of (KURA) Talks, People Listen - Stock Traders Daily

11:36 AM

09:33 AM

Kura Oncology to present AML trial data at ASH meeting - Investing.com

09:33 AM

09:31 AM

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times

09:31 AM

09:09 AM

Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com

09:09 AM

Nov 04, 2024

Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Nov 01, 2024

Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 01, 2024

Oct 31, 2024

Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024

Oct 29, 2024

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan

Oct 29, 2024

Oct 26, 2024

Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat

Oct 24, 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian

Oct 24, 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan

Oct 24, 2024

Oct 23, 2024

Kura Oncology Enters Oversold Territory (KURA) - Nasdaq

Oct 23, 2024

Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat

Oct 23, 2024

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times

Oct 23, 2024

Oct 17, 2024

Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat

Oct 17, 2024

Oct 16, 2024

Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts - MarketBeat

Oct 16, 2024

Oct 15, 2024

An analyst sees good growth prospects for Kura Oncology Inc (KURA) - SETE News

Oct 15, 2024

Where are the Opportunities in (KURA) - Stock Traders Daily

Oct 15, 2024

Oct 14, 2024

Kura downgraded to hold by Stifel, prefers rival Syndax - MSN

Oct 14, 2024

Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's Why - MarketBeat

Oct 14, 2024

This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga

Oct 14, 2024

Kura Oncology (NASDAQ:KURA) Cut to "Hold" at Stifel Nicolaus - MarketBeat

Oct 14, 2024

Stifel sees challenges for Kura Oncology stock with delayed launch in AML market - Investing.com UK

Oct 14, 2024

Oct 11, 2024

Squarepoint Ops LLC Cuts Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat

Oct 11, 2024

Oct 10, 2024

Millennium Management LLC Sells 148,734 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat

Oct 10, 2024

Oct 09, 2024